Search

Your search keyword '"Peters, Ron J.G."' showing total 104 results
Start Over Author "Peters, Ron J.G." Search Limiters Full Text
104 results on '"Peters, Ron J.G."'

5. Patients' preferences for secondary prevention following a coronary event

Author

van Trier, Tinka J., Jørstad, Harald T., Scholte op Reimer, Wilma J.M., Sunamura, Madoka, ter Hoeve, Nienke, Aernout Somsen, G., Peters, Ron J.G., Snaterse, Marjolein, van Trier, Tinka J., Jørstad, Harald T., Scholte op Reimer, Wilma J.M., Sunamura, Madoka, ter Hoeve, Nienke, Aernout Somsen, G., Peters, Ron J.G., and Snaterse, Marjolein

Abstract

Objective:Despite clear evidence on the effectiveness of secondary prevention, patients with coronary artery disease frequently fail to reach guideline-based risk factor targets. Integrating patients’ preferences into treatment decisions has been recommended to reduce this gap. However, this requires knowledge about patient treatment preferences. Therefore, through a survey study, we aimed to explore which risk factors patients self-perceived, prioritised for improvement, and needed support with after a recent hospitalisation for coronary heart disease. Methods: A digital questionnaire was presented to patients > 18 years recently discharged (≤3 months) from an acute coronary care unit in the Netherlands (Europe). Patients could select from eight cardiovascular risk factors that they (1) self-perceived, (2) prioritised for improvement, and (3) needed support to improve. Patients’ perceived risk factors were compared to those documented in the medical records. Results: Respondents (N = 254, 26 % women), mean age 64 (SD 10) years, identified ‘physical inactivity’ more frequently than their medical records (140 patients vs. 91 records, p < 0.001), while three other risk factors were reported with equal and four with lower frequency. ‘Physical inactivity’, ‘overweight’ and ‘stress’ were most frequently prioritised for improvement (82 %, 88 % and 78 %) and professional support (64 %, 50 % and 58 %), with 87 % preferring lifestyle optimisation if this would reduce drug use. Conclusions: Patients with a recent coronary event show significant disparities in identifying risk factors compared to their medical records. They tend to prefer improving lifestyle- over drug-modifiable risk factors, particularly physical inactivity, overweight and stress, and indicate the need for support in improving these factors.

Published
2024

6. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

Author

van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., Jørstad, Harald T., van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., and Jørstad, Harald T.

Abstract

BACKGROUND: Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. AIMS: This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. METHODS AND RESULTS: Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged ≥45 years at ≥6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had ≥1 drug-modifiable risk factor not on target. Furthermore, 91% had ≥1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. CONCLUSIONS: Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.

Published
2023

7. Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

Author

Interne Geneeskunde Vasculaire, Circulatory Health, van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., Jørstad, Harald T., Interne Geneeskunde Vasculaire, Circulatory Health, van Trier, Tinka J., Snaterse, Marjolein, Hageman, Steven H.J., Ter Hoeve, Nienke, Sunamura, Madoka, Moll van Charante, Eric P., Galenkamp, Henrike, Deckers, Jaap W., Martens, Fabrice M.A.C., Visseren, Frank L.J., Scholte Op Reimer, Wilma J.M., Peters, Ron J.G., and Jørstad, Harald T.

Published
2023

10. Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention: A Cohort Study in ST-Segment Elevation Myocardial Infarction and Comprehensive Meta-analysis

Author

Kikkert, Wouter J., Delewi, Ronak, Ouweneel, Dagmar M., van Nes, Sophie H., Vis, Marije M., Baan, Jan, Jr., Koch, Karel T., Dangas, George D., Mehran, Roxana, de Winter, Robbert J., Peters, Ron J.G., Piek, Jan J., Tijssen, Jan G.P., and Henriques, Jose P.S.

Published
2014
Full Text
View/download PDF

11. Sarcopenia and its relation to protein intake across older ethnic populations in the Netherlands: the HELIUS study

Author

Dorhout, Berber G., Overdevest, Elvera, Tieland, Michael, Nicolaou, Mary, Weijs, Peter J.M., Snijder, Marieke B., Peters, Ron J.G., Van Valkengoed, Irene G.M., Haveman-Nies, Annemien, De Groot, Lisette C.P.G.M., Dorhout, Berber G., Overdevest, Elvera, Tieland, Michael, Nicolaou, Mary, Weijs, Peter J.M., Snijder, Marieke B., Peters, Ron J.G., Van Valkengoed, Irene G.M., Haveman-Nies, Annemien, and De Groot, Lisette C.P.G.M.

Abstract

Objective: To examine the prevalence of sarcopenia and its association with protein intake in men and women in a multi-ethnic population.Design: We used cross-sectional data from the HELIUS (Healthy Life in an Urban Setting) study, which includes nearly 25,000 participants (aged 18–70 years) of Dutch, South-Asian Surinamese, African Surinamese, Turkish, Moroccan, and Ghanaian ethnic origin. For the current study, we included 5161 individuals aged 55 years and older. Sarcopenia was defined according to the EWGSOP2. In a subsample (N = 1371), protein intake was measured using ethnic-specific Food Frequency Questionnaires. Descriptive analyses were performed to study sarcopenia prevalence across ethnic groups in men and women, and logistic regression analyses were used to study associations between protein intake and sarcopenia.Results: Sarcopenia prevalence was found to be sex- and ethnic-specific, varying from 29.8% in Turkish to 61.3% in South-Asian Surinamese men and ranging from 2.4% in Turkish up to 30.5% in South-Asian Surinamese women. Higher protein intake was associated with a 4% lower odds of sarcopenia in the subsample (OR = 0.96, 95%-CI: 0.92–0.99) and across ethnic groups, being only significant in the South-Asian Surinamese group.Conclusion: Ethnic differences in the prevalence of sarcopenia and its association with protein intake suggest the need to target specific ethnic groups for prevention or treatment of sarcopenia.

Published
2022

12. Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making

Author

Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Circulatory Health, MS Interne Geneeskunde, de Vries, Tamar I., Stam-Slob, Manon C., Peters, Ron J.G., van der Graaf, Yolanda, Westerink, Jan, Visseren, Frank L.J., Interne Geneeskunde Vasculaire, Unit Opleiding Aios, Circulatory Health, MS Interne Geneeskunde, de Vries, Tamar I., Stam-Slob, Manon C., Peters, Ron J.G., van der Graaf, Yolanda, Westerink, Jan, and Visseren, Frank L.J.

Published
2022

26. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Author

Lonn, Eva, Bosch, Jackie, Pogue, Janice, Avezum, Alvaro, Chazova, Irina, Dans, Antonio, Diaz, Rafael, Fodor, George J., Held, Claes, Jansky, Petr, Keltai, Matyas, Keltai, Katalin, Kunti, Kamlesh, Kim, Jae Hyung, Leiter, Lawrence A., Lewis, Basil S., Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Parkhomenko, Alexander, Peters, Ron J.G., Piegas, Leopoldo S., Reid, Christopher M., Sliwa, Karen, Toff, William D., Varigos, John, Xavier, Denis, Yusoff, Khalid, Zhu, Jun, Dagenais, Gilles, Yusuf, Salim, The HOPE-3 Investigators, Amsterdam Cardiovascular Sciences, Amsterdam Public Health, and Cardiology

Subjects
Male, Tetrazoles, Blood Pressure, 030204 cardiovascular system & hematology, Global Health, law.invention, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, 030212 general & internal medicine, Myocardial infarction, Rosuvastatin Calcium, Diuretics, Incidence, Middle Aged, Primary Prevention, Cholesterol, Hydrochlorothiazide, Treatment Outcome, Cardiovascular Diseases, Population Surveillance, Blood pressure, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, Cardiovascular Disease Prevention, medicine.drug, medicine.medical_specialty, Statin, medicine.drug_class, COLESTEROL, Placebo, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, Rosuvastatin, Risk factor, Contraindication, Aged, Dose-Response Relationship, Drug, business.industry, Biphenyl Compounds, Cholesterol, LDL, medicine.disease, Surgery, Clinical trial, Benzimidazoles, business, Angiotensin II Type 1 Receptor Blockers
Abstract

8 p., Résumé Introduction Il est possible de faire baisser efficacement et en toute sécurité le cholestérol et la pression artérielle (PA) avec les statines et les antihypertenseurs tout en réduisant de 20 à 30 % les manifestations cardiovasculaires majeures en l’espace de cinq ans chez les personnes à risque élevé. Les données obtenues dans les populations exposées à un risque plus faible sont néanmoins limitées. L’essai HOPE-3 (Heart Outcomes Prevention Evaluation-3) tâche de déterminer si l’abaissement du cholestérol à l’aide d’une statine, l’abaissement de la pression artérielle à l’aide de deux agents antihypertenseurs administrés à raison d’une faible dose et leur association permettent de réduire en toute sécurité les manifestations cardiovasculaires majeures chez les personnes exposées à un risque intermédiaire qui n’ont pas d’antécédents d’événements vasculaires et dont le taux de cholestérol et la PA se situent dans la moyenne. Méthodes Au total, 12 705 femmes et hommes, les unes âgées de 65 ans et plus et les autres de 55 ans et plus, qui présentent au moins un facteur de risque cardiovasculaire et qui n’ont pas de maladie cardiovasculaire connue ni aucune indication ou contre-indication claires aux médicaments à l’étude, ont été répartis aléatoirement pour recevoir de la rosuvastatine à raison de 10 mg par jour ou un placebo et l’association candésartan/hydrochlorothiazide à raison de 16/12,5 mg par jour ou un placebo (plan factoriel 2 × 2). Ces patients seront suivis pendant une moyenne de 5,8 ans. Les principaux paramètres d’évaluation de l’étude combinent le décès d’origine cardiovasculaire, l’infarctus du myocarde non mortel et l’AVC non mortel d’une part, et le décès d’origine cardiovasculaire, l’infarctus du myocarde non mortel, l’AVC non mortel, la réanimation après arrêt cardiaque, l’insuffisance cardiaque et la revascularisation artérielle d’autre part. Résultats Les participants ont été recrutés dans 21 pays situés en Amérique du Nord, en Amérique du Sud, en Europe, en Asie et en Australie. L’âge moyen au moment de la répartition aléatoire était de 66 ans, et 46 % des sujets étaient des femmes. Conclusions L’essai HOPE-3 fournira de nouveaux renseignements sur l’abaissement du taux de cholestérol et de la PA dans des populations exposées à un risque intermédiaire dont le taux de cholestérol et la PA se situent dans la moyenne. Il devrait également fournir des données à l’appui des stratégies de prévention primaire mises en place partout dans le monde (HOPE-3 ClinicalTrials.gov NCT00468923)., Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels. Methods A total of 12,705 women 65 years or older and men 55 years or older with at least 1 CV risk factor, no known CV disease, and without any clear indication or contraindication to the study drugs were randomized to rosuvastatin 10 mg/d or placebo and to candesartan/hydrochlorothiazide 16/12.5 mg/d or placebo (2 × 2 factorial design) and will be followed for a mean of 5.8 years. The coprimary study outcomes are the composite of CV death, nonfatal myocardial infarction (MI), and nonfatal stroke and the composite of CV death, nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, heart failure, and arterial revascularization. Results Participants were recruited from 21 countries in North America, South America, Europe, Asia, and Australia. Mean age at randomization was 66 years and 46% were women. Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov NCT00468923).

Published
2016

28. Effects of Primary Cardiovascular Prevention on Vascular Risk in Older Adults

Author

Bussel, Emma F. van, Hoevenaar-Blom, Marieke P., Busschers, Wim B., Richard, E., Peters, Ron J.G., Gool, Willem A. van, Charante, Eric P.Moll van, Bussel, Emma F. van, Hoevenaar-Blom, Marieke P., Busschers, Wim B., Richard, E., Peters, Ron J.G., Gool, Willem A. van, and Charante, Eric P.Moll van

Abstract

Contains fulltext : 195136.pdf (Publisher’s version ) (Open Access)

Published
2018

29. Grenzen aan de behandeling van hypertensie

Author

Kalkman, Deborah N., Brouwer, Tom F., Spiering, Wilko, Peters, Ron J.G., Van Den Born, Bert Jan H., Kalkman, Deborah N., Brouwer, Tom F., Spiering, Wilko, Peters, Ron J.G., and Van Den Born, Bert Jan H.

Published
2018

30. Grenzen aan de behandeling van hypertensie

Author

Interne Geneeskunde Vasculaire, MS Interne Geneeskunde, Circulatory Health, Kalkman, Deborah N., Brouwer, Tom F., Spiering, Wilko, Peters, Ron J.G., Van Den Born, Bert Jan H., Interne Geneeskunde Vasculaire, MS Interne Geneeskunde, Circulatory Health, Kalkman, Deborah N., Brouwer, Tom F., Spiering, Wilko, Peters, Ron J.G., and Van Den Born, Bert Jan H.

Published
2018

31. Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease

Author

Minneboo, Madelon, primary, Lachman, Sangeeta, additional, Snaterse, Marjolein, additional, Jørstad, Harald T., additional, ter Riet, Gerben, additional, Boekholdt, S. Matthijs, additional, Scholte op Reimer, Wilma J.M., additional, Peters, Ron J.G., additional, Riezebos, R.K., additional, van Liebergen, R.A.M., additional, van der Spank, A., additional, van Dantzig, J.M., additional, de Milliano, P.A.R., additional, van Hessen, M.W.J., additional, Kragten, J.A., additional, Jaarsma, W., additional, den Hartog, F.R., additional, Bartels, G.L., additional, Aengevaeren, W.R.M., additional, van Rossum, P., additional, Anneveldt, A., additional, and de Vries, C.J., additional

Published
2017
Full Text
View/download PDF

32. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population

Author

Kaasenbrood, Lotte, primary, Boekholdt, S. Matthijs, additional, van der Graaf, Yolanda, additional, Ray, Kausik K., additional, Peters, Ron J.G., additional, Kastelein, John J.P., additional, Amarenco, Pierre, additional, LaRosa, John C., additional, Cramer, Maarten J.M., additional, Westerink, Jan, additional, Kappelle, L. Jaap, additional, de Borst, Gert J., additional, and Visseren, Frank L.J., additional

Published
2016
Full Text
View/download PDF

36. A clinical prediction model for the presence of peripheral arterial disease — the benefit of screening individuals before initiation of measurement of the ankle—brachial index: an observational study

Author

Bendermacher, Bianca L.W., primary, Teijink, Joep A.W., additional, Willigendael, Edith M., additional, Bartelink, Marie-Louise, additional, Peters, Ron J.G., additional, de Bie, Rob A., additional, Büller, Harry R., additional, Boiten, Jelis, additional, Langenberg, Machteld, additional, and Prins, Martin H., additional

Published
2007
Full Text
View/download PDF

38. Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention

Author

Mehta, Shamir R., primary, Steg, Philippe Gabriel, additional, Granger, Christopher B., additional, Bassand, Jean-Pierre, additional, Faxon, David P., additional, Weitz, Jeffrey I., additional, Afzal, Rizwan, additional, Rush, Bonnie, additional, Peters, Ron J.G., additional, Natarajan, Madhu K., additional, Velianou, James L., additional, Goodhart, David M., additional, Labinaz, Marino, additional, Tanguay, Jean-Francois, additional, Fox, Keith A.A., additional, and Yusuf, Salim, additional

Published
2005
Full Text
View/download PDF

39. Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women

Author

Boekholdt, S. Matthijs, primary, Kuivenhoven, Jan-Albert, additional, Wareham, Nicholas J., additional, Peters, Ron J.G., additional, Jukema, J. Wouter, additional, Luben, Robert, additional, Bingham, Sheila A., additional, Day, Nicholas E., additional, Kastelein, John J.P., additional, and Khaw, Kay-Tee, additional

Published
2004
Full Text
View/download PDF

50. Prediction of Restenosis After Coronary Balloon Angioplasty

Author

Peters, Ron J.G., primary, Kok, Wouter E.M., additional, Di Mario, Carlo, additional, Serruys, Patrick W., additional, Bär, Frits W.H.M., additional, Pasterkamp, Gerard, additional, Borst, Cornelis, additional, Kamp, Otto, additional, Bronzwaer, Jean G.F., additional, Visser, Cees A., additional, Piek, Jan J., additional, Panday, Radjan N., additional, Jaarsma, Wiebe, additional, Savalle, Lucas, additional, and Bom, Nicolaas, additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results